Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007

Antiviral Therapy

Volumn 14, Issue 5, 2009, Pages 673-678

  Hurt, Christopher B ^a   McCoy, Sandra I ^b   Kuruc, JoAnn ^a   Nelson, Julie A E ^a,c   Kerkau, Melissa ^a,c   Fiscus, Susan ^a,c   McGee, Kara ^d   Sebastian, Joseph ^e   Leone, Peter ^a,f   Pilcher, Christopher ^g   Hicks, Charles ^d   Eron Jr , Joseph ^a,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d DUKE UNIVERSITY   (United States)

^e LABORATORY CORPORATION OF AMERICA   (United States)

^f NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SEQUENCE; GENOTYPE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; VIRUS TRANSMISSION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; NORTH CAROLINA; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POPULATION SURVEILLANCE; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 69849107234     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368.
2. Grant RM, Hecht FM, Warmerdam. M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
3. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
4. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322:1087-1088.
5. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180.
6. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
7. UK Collaborative Group on HIV Drug Resistance. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007; 21:1035-1039.
8. Probst JC, Moore CG, Glover SH, Samuels ME. Person and place: the compounding effects of race/ethnicity and rurality on health. Am J Public Health 2004; 94:1695-1703.
9. Eberhardt MS, Pamuk ER. The importance of place of residence: examining health in rural and nonrural areas. Am J Public Health 2004; 94:1682-1686.
10. Fleming PL, Lansky A, Lee LM, Nakashima AK. The epidemiology of HIV/AIDS in women in the southern United States. Sex Transm Dis 2006; 33 Suppl 7:S32-S38.
11. Milhausen RR, Crosby R, Yarber WL, DiClemente RJ, Wingood GM, Ding K. Rural and nonrural African American high school studentsand STD/HIV sexual-risk behaviors. Am J Health Behav 2003; 27:373-379.
12. Rothenberg R, Baldwin J, Trotter R, Muth S. The risk environment for HIV transmission: results from the Atlanta and Flagstaff network studies. J Urban Health 2001; 78:419-432.
13. Sateren WB, Renzullo PO, Carr JK, Birx DL, McNeil JG. HIV-1 infection among civilian applicants for US military service, 1985 to 2000: epidemiology and geography. J Acquir Immune Defic Syndr 2003; 32:215-222.
14. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep 2008; 56:1-124.
15. Pilcher CD, McPherson JT, Leone PA, et al. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA 2002; 288:216-221.
16. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infectious during HIV testing in North Carolina. N Engl J Med 2005; 352:1873-1883.
17. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 2001; 15:837-845.
18. The Kaiser Family Foundation. Population distribution by metropolitan status, states (2006-2007), U.S. (2007). (Updated March 2008. Accessed 26 February 2009.) Available from http://www.statehealthfacts.org/ comparetable.jsp?ind=18&cat=18csub=4&yr=85&ctyp=2
19. Rezk NL, Crutchley RD, Kashuha AD. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 822:201-208.
20. Rezk NL, Tidwell RR, Kashuba AD. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791:137-147.
21. Choi SO, Rezk NL, Kashuba AD. High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. J Pharm Biomed Anal 2007; 43:1562-1567.
22. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31:298-303.
23. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223.
24. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
25. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 2001; 98:13907-13912.
26. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18:227-235.
27. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-1873.
28. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
29. Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002). Int J STD AIDS 2008; 19:297-304.
30. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services; January 29 2008. (Updated 29 January 2008. Accessed 10 August 2008.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
31. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT. The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr 2008; 49:196-204.